Instructions to Submitters

• Every new user MUST begin by creating a new account.
• Ensure all email addresses are correct.
• Inactivity of more than 90 minutes on the system pages will result in a session time out. Please save your pages intermittently to avoid loss of data.
• If you need technical or association assistance, please use the email support form on each page.
• Once you have completed all sections, please click on ‘finalize submission’ on the final page to complete your submission.
• Revisit the site as often as necessary to complete your submission.
• Users must use the following browsers: Internet Explorer 8+, Mozilla Firefox 4+, Safari 5+, Chrome 14+, Opera 11.5+
  The back and forward browser arrows have been disabled; please use the menu progress bar at the top right-hand corner of the pages to return to previous pages.
• At any point in the abstract process, the submitter of the abstract can log into submission to view your abstract details and any correspondence about your submission(s).
• Note on email communications: Please add @owpm1.com as a safe sender in your email program. If you do not do this, your email spam filter may prevent you from receiving important emails regarding your submission(s).  For more information on adding safe senders for your mail server, click here. 

Guidelines

Participants interested in presenting data should submit abstracts online by July 31st, 2024, 11:59PM ET. Abstracts are subject to acceptance by the Congress Chairs. Once accepted, abstracts will be published in the American Journal of Hematology, on the Oncology Learning Network website, and scheduled for digital poster display at the 2024 LL&M Congress. The best abstracts will be invited for oral presentation. Only abstracts received by the submission deadline will be published. There will be no additional deadlines for late-breaking data. Acceptance notifications will be sent on or before September 12, 2024.  Authors of accepted abstracts who have not registered will have until October 3, 2024 to do so at the early registration rate. After this date, abstracts without registered presenters will be disregarded and not included in the publication.

Abstracts will be accepted in the following categories:  ACUTE LEUKEMIA & MYELOPROLIFERATIVE/MYELODYSPLASTIC DISEASES or MULTIPLE MYELOMA or CHRONIC LYMPHOCYTIC LEUKEMIA or LYMPHOMA. Please indicate which category is appropriate by checking the appropriate box in the online submission system.

Industry authors can be a co-author, but they cannot be the lead and/or senior author. Further, Industry authors cannot be the ones to present the research on site at LLM. 

Abstract Guidelines

• Please follow the online instructions
• Abstracts must be in English
• 9 point Arial font
• Abstract body must have a 500 word count limit
• Use a concise title in title case only.  (Example:  This is the Title of my Presentation)
• List affiliations of author(s) as briefly as possible, with city, state/province and country
• Maximum number of authors: 20
• Use standard and well-accepted abbreviations
• When using references, use standard and well-accepted formats
• Abstract content should be single-spaced and typed in lower case; abstract title should not include any formatting.
• Abstracts shall be of original research and contain a concise statement of study aim.
• Abstracts should be structured as to include the following sections:

For Completed Studies include 4 sections. Authors may use the following headings (or similar) when preparing the abstract:

1. Introduction/Background/Significance,

2. Materials and Methods/Case Presentation/Objectives

3. Results/Description/Main Outcome Measure(s), and

4. Conclusion(s). Conclusions must be supported by your results and summarized within your abstract at the time of submission. Results “to be completed” and/or conclusions “to be discussed” are not acceptable.

For Abstracts of Clinical Trials in Progress (eg; results not yet available; 3 sections): Background, Design and Methods, Status

Trials in Progress Abstract Submissions

The 2024 Lymphoma, Leukemia & Myeloma Congress is now accepting Trials in Progress abstract submissions in all phases of clinical research (phase I to phase III). All abstracts submitted as Trials in Progress are ongoing trials that have not reached any protocol-specific endpoint for analysis and will only require the completion of two sections: Background and Trial Design. It is a requirement that recruitment must have already begun or have been completed by the abstract submission deadline.

Previous Presentation, Publication and Duplication of Abstracts:

• Encore abstracts will be allowed if they contain new data. During the submission process you will be asked if the abstract has been presented before, when you say yes you will be prompted to submit the original abstract as a reference
• Abstracts will not be considered for presentation if they have been or will be published as an article (includes manuscripts accepted for publication) in either printed or electronic format upon the abstract submission deadline.
• Abstracts will not be considered for presentation if they have been duplicated in any way.
• Abstracts may not be submitted to more than one category.
• Abstracts that have been submitted to the Lymphoma & Myeloma Congress in previous years, and have not been accepted for poster presentation, are eligible for submission but must contain new, additional information to be considered.
• Violations of these policies could result in a sanction from submitting abstracts to this congress for the submitting author.

Digital Poster Advantages

• Integration of posters into Exhibit Hall, thus no separate poster hall to walk to.
• No Paper Required - Poster presenters do not produce a paper version of the poster.
• No Setup time or tear down time required.

Commitment to Present
Submission of an abstract constitutes a commitment by the author(s) to 1) provide an appropriately formatted abstract poster to showcase as a digital poster, 2) conduct an oral presentation if selected as the winning abstract for the category (i.e. Best of Lymphoma Abstract). Failure to present, if not justified, will jeopardize acceptance of future abstract submissions. Only the presenting author or co-author may present the accepted abstract at the 2024 LL&M Congress.

The congress will withdraw abstracts upon written notification from the submitting author by September 24, 2024. If circumstances prevent attendance, the primary author must arrange for the poster to be in the poster hall and/or presented by a co-author. Acceptance of the abstract obligates the author to present the paper.